文献速递头颈部肿瘤放疗

阿瓦索帕生锰对头颈癌患者严重口腔黏膜炎的获益:ROMAN试验的非计划二次分析

Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis.
PubMed 文献 · Adv Radiat Oncol · 2024-11-09

ROMAN 3期试验的非计划二次分析采用广义配对比较法,对407例(AVA组241例、安慰剂组166例)头颈癌患者按顺铂方案和治疗场景分层,共进行13,969次配对比较。AVA在全部4项关键结局上显示净获益,AVA获益概率53.9% vs 安慰剂35.0%,净治疗获益18.9%(P=0.0012),需治疗人数为5.3例。

要点

  • AVA组241例、安慰剂组166例,按顺铂方案和治疗场景分层后行广义配对比较。
  • AVA获益概率53.9% vs 安慰剂35.0%,净治疗获益18.9%(P=0.0012)。
  • AVA需治疗人数为5.3例,4项关键结局均对净获益有贡献。

核心结论

  • 广义配对比较分析显示,ROMAN试验中AVA在严重口腔黏膜炎负担的关键参数上具有临床获益的有力证据。

研究设计与样本

  • ROMAN 3期试验的非计划二次分析,采用广义配对比较法同时分析多项优先结局。
  • 共纳入407例患者,其中AVA组241例、安慰剂组166例,按顺铂方案和治疗场景分层,进行13,969次配对比较。

主要发现

  • AVA在全部4项关键结局上显示统计学显著的净获益:AVA获益概率53.9% vs 安慰剂35.0%,差值即净治疗获益18.9%(P=0.0012)。
  • 净治疗获益18.9%对应AVA需治疗人数为5.3例。
  • 全部结局均对净治疗获益有贡献,反映严重口腔黏膜炎发生率、发生时间和持续时间以及WHO 4级口腔黏膜炎发生率的改善。

关键数值与推荐

  • 优先结局依次为:WHO 4级口腔黏膜炎发生率、严重口腔黏膜炎发生率、严重口腔黏膜炎天数、至严重口腔黏膜炎发生时间。
  • 严重口腔黏膜炎天数和发生时间的临床相关性阈值定义为7天差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oral mucositis (OM) is a debilitating side effect of cisplatin and intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer. The phase 3 ROMAN trial showed avasopasem manganese (AVA) significantly decreased individual endpoints of incidence and duration of severe oral mucositis (SOM, World Health Organization [WHO] grade 3-4), with nominal decrease in severity (WHO grade 4) and significant increase in the delay in onset of SOM. We sought to determine the Net Treatment Benefit (NTB) of AVA versus placebo (PBO) using the generalized pairwise comparisons (GPC) method. METHODS AND MATERIALS: GPC is a statistical method that permits simultaneous analysis of several prioritized outcomes, comparing all possible pairs of a patient in the active (ie, AVA) group and a patient from the control (ie, PBO) group. NTB is the net benefit across all the outcomes for AVA compared to PBO. Key clinically relevant outcomes from ROMAN were prioritized: (1) WHO grade 4 OM incidence; (2) SOM incidence; (3) days of SOM; (4) days to SOM onset, with 7 days difference defined as the clinical relevance threshold for SOM days and SOM onset. RESULTS: GPC analysis of 407 patients (AVA = 241, placebo = 166) stratified by cisplatin schedule and treatment setting resulted in 13,969 pairwise comparisons. AVA showed statistically significant net benefit on all 4 key outcomes with a 53.9% probability that AVA would benefit patients versus a 35.0% probability that PBO would; the difference between these probabilities was a NTB of 18.9% (P = .0012), translating to an AVA number needed to treat of 5.3 patients. All outcomes contributed to NTB, reflecting improvements in SOM incidence, onset and duration, and in grade 4 OM incidence seen in the original ROMAN analysis. CONCLUSIONS: This GPC analysis shows compelling evidence from the ROMAN trial of AVA's clinical benefit across key parameters of SOM burden.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Anderson C, Salvaggio S, De Backer M, et al. Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis. Adv Radiat Oncol. 2024. PMID: 39678920. doi:10.1016/j.adro.2024.101674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。